Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nipent pentostatin: Phase I; marketed to treat hairy cell leukemia

In a Phase I study of 3 patients with chronic

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE